Last $121.69 USD
Change Today +0.47 / 0.39%
Volume 182.8K
TFX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

teleflex inc (TFX) Snapshot

Open
$120.74
Previous Close
$121.22
Day High
$122.16
Day Low
$120.56
52 Week High
02/23/15 - $123.09
52 Week Low
04/28/14 - $99.56
Market Cap
5.0B
Average Volume 10 Days
356.3K
EPS TTM
$4.39
Shares Outstanding
41.4M
EX-Date
02/27/15
P/E TM
27.7x
Dividend
$1.36
Dividend Yield
1.12%
Current Stock Chart for TELEFLEX INC (TFX)

Related News

No related news articles were found.

teleflex inc (TFX) Related Businessweek News

No Related Businessweek News Found

teleflex inc (TFX) Details

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products for critical care therapies, including the administration of intravenous medications and other therapies, the measurement of blood pressure, and taking of blood samples through a single puncture site; and anesthesia products, such as airway management products under the LMA and Rusch brands, and pain management products under the Arrow brand. The company also provides respiratory care products, such as oxygen therapy, aerosol therapy, spirometry, and ventilation management products under the Hudson RCI brand. In addition, it offers surgical products, such as ligation clips and closure products; appliers and sutures used in surgical procedures; access ports for use in minimally invasive laparoscopic surgical procedures; robotic surgery and fluid management products for use in chest drainage; and reusable hand-held instruments for surgical procedures under the Deknatel, Pilling, Pleur-evac, Taut, and Weck brands. Further, the company offers cardiac care products comprising diagnostic catheters, including thermodilution and wedge pressure catheters; specialized catheters; therapeutic delivery catheters; sheaths for femoral and trans-radial aortic access, and intra-aortic balloons; and capital equipment, such as intra-aortic balloon pumps under the Arrow brand. Additionally, it provides catheters, urine collectors, catheterization accessories, and products for operative endourology under the Rusch brand name; micro-laparoscopic instrumentation products; and original equipment manufacturing services. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.

11,700 Employees
Last Reported Date: 02/20/15
Founded in 1943

teleflex inc (TFX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $826.6K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $441.5K
Executive Vice President and President of Ame...
Total Annual Compensation: $427.1K
Compensation as of Fiscal Year 2013.

teleflex inc (TFX) Key Developments

Teleflex Launches Triple-Lumen PICC with Chlorag+ard Technology

Teleflex Incorporated has launched a triple-lumen ARROW peripherally inserted central catheter, or PICC, with Chlorag+ard Technology. Pressure-injectable ARROW PICCs with Chlorag+ard Technology are the world's first FDA-cleared central venous catheters to significantly reduce the risk of central line-associated bloodstream infections (CLABSI) and PICC-related vessel thrombosis, compared to traditional uncoated catheters. They are also the only PICCs in the IV catheter marketplace that have received FDA 510(k) clearance for both broad-spectrum antimicrobial and antithrombogenic protection. Hospitals and clinicians have increasingly focused on reducing CLABSI and catheter-related vessel thrombosis when inserting PICCs, which are widely used in acute-care and long-term care settings. In addition to CLABSI and thrombosis, the ARROW PICC with Chlorag+ard Technology protects against thrombotic, intraluminal catheter occlusion, the most common non-infectious complication in the long-term use of central lines. Occlusions can delay patient therapy and also require the use of expensive de-clotting agents. Chlorag+ard Technology uses a proprietary process to chemically bond chlorhexidine to both the internal and external surfaces of the catheter. The chlorhexidine-bonded surfaces, which provide a controlled release of the broad-spectrum antimicrobial, are the key to the PICC's antimicrobial and antithrombogenic benefits. The FDA clearance for ARROW PICCs with Chlorag+ard Technology states that these IV catheters provide less thrombus accumulation for at least 30 days. In Vitro data establishes that the device provides 99.99% colonization reduction against gram + and gram - bacteria and fungi for at least 30 days.

Teleflex Incorporated Declares Quarterly Dividend, Payable on March 16, 2015

Teleflex Incorporated announced that its Board of Directors declared a quarterly cash dividend of 34 cents ($0.34) per share of common stock. The dividend is payable March 16, 2015 to shareholders of record at the close of business on March 3, 2015.

Teleflex Incorporated Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

Teleflex Incorporated reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the fourth quarter 2014, the company’s net revenues were $476.0 million, an increase of 5.7% over $450.54 million for the prior year period. Excluding the impact of foreign currency fluctuations, fourth quarter 2014 net revenues increased 9.0% over the prior year period. GAAP diluted earnings per share from continuing operations were $1.10, as compared to $0.78 in the prior year period, an increase of 41.0%. Fourth quarter 2014 adjusted diluted earnings per share from continuing operations were $1.43, as compared to $1.36 in the prior year period, an increase of 5.1%. Income from continuing operations before interest and taxes was $69,155,000 compared to $54,064,000 a year ago. Income from continuing operations before taxes was $52,559,000 compared to $39,891,000 a year ago. Income from continuing operations was $52,133,000 compared to $35,302,000 a year ago. Net income attributable to common shareholders was $50,638,000 or $1.07 per diluted share, compared to $34,828,000 or $0.77 per diluted share, a year ago. For the full year 2014, the company’s net revenues were $1.84 billion, an increase of 8.5% $1.7 billion over the prior year period. Excluding the impact of foreign currency fluctuations, full year 2014 net revenues increased 8.8% over the prior year period. GAAP diluted earnings per share from continuing operations were $4.10, as compared to $3.46 in the prior year period, an increase of 18.5%. Full year 2014 adjusted diluted earnings per share from continuing operations were $5.74, as compared to $5.03 in the prior year period, an increase of 14.1%. Net debt obligations at December 31, 2014 were $801.4 million compared to $902.7 million at December 31, 2013. Income from continuing operations before interest and taxes was $284,862,000 compared to $233,261,000 a year ago. Income from continuing operations before taxes was $220,110,000 compared to $175,730,000 a year ago. Income from continuing operations was $191,460,000 compared to $152,183,000 a year ago. Net income attributable to common shareholders was $187,679,000 or $4.04 per diluted share, compared to $150,881,000 or $3.45 per diluted share, a year ago. Net cash provided by operating activities from continuing operations was $290,241,000 compared to $231,299,000 a year ago. Expenditures for property, plant and equipment were $67,571,000 compared to $63,580,000 a year ago. Payments for businesses and intangibles acquired, net of cash acquired were $45,777,000 compared to $309,008,000 a year ago. The company provided earnings guidance for the full year of 2015. The company estimates that revenues for full year 2015 will increase 4% to 6% on a constant currency basis. On a GAAP basis, revenues are expected to be flat to down 2% versus the prior year due to the unfavorable impact of foreign currency. The company expects adjusted diluted earnings per share from continuing operations to be between $6.10 and $6.35 for full year 2015, representing an increase of 6.3% to 10.6% over the prior year, which reflects the company expectation of a negative foreign currency headwind of approximately 14%. The company expects full year 2015 GAAP diluted earnings per share from continuing operations to be between $4.22 and $4.37. The company anticipates that its 2015 results will be negatively impacted by foreign exchange movements, the company is committed to implementing operational measures to, in part, mitigate the earnings effect.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TFX:US $121.69 USD +0.47

TFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Donaldson Co Inc $37.04 USD -0.13
PerkinElmer Inc $47.00 USD 0.00
Sirona Dental Systems Inc $90.82 USD -0.20
STERIS Corp $64.52 USD +0.23
West Pharmaceutical Services Inc $54.72 USD -0.23
View Industry Companies
 

Industry Analysis

TFX

Industry Average

Valuation TFX Industry Range
Price/Earnings 29.6x
Price/Sales 2.7x
Price/Book 2.6x
Price/Cash Flow 26.8x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TELEFLEX INC, please visit www.teleflex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.